Orchid receives final USFDA nod for Rasagiline generic formulation

17 Mar 2016 Evaluate

Orchid Pharma has received final approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Rasagiline Tablets 0.5 mg and 1 mg. This product is a FTF (First-to-file) application with a shared 180-day exclusivity for Orchid. Orchid expects to launch this product in Q4 of FY16-17.

Rasagiline Mesylate Tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. With a market size of over $ 300 million and limited generic competition, Orchid hopes to garner a decent market share from this product launch.

Orchid Pharma Share Price

645.85 -19.40 (-2.92%)
24-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1730.55
Dr. Reddys Lab 1299.40
Cipla 1326.30
Zydus Lifesciences 904.35
Lupin 2251.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×